Nationwide Fund Advisors’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-31,900
| Closed | -$5.74M | – | 3050 |
|
|
2017
Q3 | $5.74M | Sell |
31,900
-19,636
| -38% | -$2.74M | 0.02% | 961 |
|
|
2017
Q2 | $5.34M | Buy |
51,536
+2,248
| +5% | +$183K | 0.02% | 975 |
|
|
2017
Q1 | $3.87M | Sell |
49,288
-3,159
| -6% | -$195K | 0.02% | 1107 |
|
|
2016
Q4 | $2.35M | Buy |
52,447
+4,167
| +9% | +$204K | 0.01% | 1345 |
|
|
2016
Q3 | $2.7M | Buy |
48,280
+11,180
| +30% | +$623K | 0.01% | 1251 |
|
|
2016
Q2 | $1.85M | Buy |
37,100
+4,398
| +13% | +$216K | 0.01% | 1396 |
|
|
2016
Q1 | $1.52M | Buy |
32,702
+9,213
| +39% | +$446K | 0.01% | 1485 |
|
|
2015
Q4 | $1.45M | Sell |
23,489
-2,014
| -8% | -$142K | 0.01% | 1521 |
|
|
2015
Q3 | $1.42M | Sell |
25,503
-22,679
| -47% | -$1.43M | 0.01% | 1546 |
|
|
2015
Q2 | $2.94M | Buy |
48,182
+15,078
| +46% | +$860K | 0.01% | 1227 |
|
|
2015
Q1 | $1.91M | Buy |
33,104
+18,832
| +132% | +$1.26M | 0.01% | 1513 |
|
|
2014
Q4 | $823K | Buy |
14,272
+4,066
| +40% | +$171K | ﹤0.01% | 1912 |
|
|
2014
Q3 | $291K | Buy |
+10,206
| New | +$253K | ﹤0.01% | 2511 |
|
Nationwide Fund Advisors's KITE Position: Q4 2017 in Review
Nationwide Fund Advisors sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 31,900 shares — an estimated $5.74M sold.
Nationwide Fund Advisors first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $5.74M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Nationwide Fund Advisors reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Nationwide Fund Advisors sold 31,900 Kite Pharma, Inc. shares in Q4 2017, an estimated $5.74M.
- Nationwide Fund Advisors first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Nationwide Fund Advisors's Kite Pharma, Inc. position peaked at $5.74M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.